Method for promoting wound healing.

1 . A method of promoting wound healing in a patient, the method comprising: applying on the wound a composition including an amino-acid based polymer, wherein the amino-acid based polymer is selected from

(1) a poly (ester amide urea) wherein at least one diol, at least one diacid, and at least one amino acid are linked together through an ester bond, an amide bond, and a urea bond,

(2) a poly (ester urethane urea) wherein at least one diol and at least one amino acid are linked together through an ester bond, a urethane bond, and a urea bond,

(3) a poly (ester amide urethane urea) wherein at least one diol, at least one diacid, and at least one amino acid are linked together through an ester bond, an amide bond, a urethane bond, and a urea bond,

(4) a poly (ester amide urethane) wherein at least one diol, at least one diacid, and at least one amino acid are linked together through an ester bond, an amide bond, and a urethane bond,

(5) a poly (ester urea) wherein at least one diol and at least one amino acid are linked together through an ester bond and a urea bond, and

(6) a poly (ester urethane) wherein at least one diol and at least one amino acid are linked together through an ester bond and a urethane bond,

further wherein

the at least one diol is a compound of formula:

HO—R 1 —OH, R 1 is chosen from C 2 -C 12 alkylene optionally interrupted by at least one oxygen, C 3 -C 8 cycloalkylene, C 3 -C 10 cycloalkylalkylene,

the at least one diacid is a compound of formula:

HO—(CO)—R 3 —(CO)—OH, R 3 is C 2 -C 12 alkylene,

the at least one amino acid is chosen from naturally occurring amino acids and non-naturally occurring amino acid.

2 . The method as defined in claim 1 , wherein the amino-acid based polymer is a poly (ester amide urea) comprising the following two blocks with random distribution thereof:

wherein

the ratio of l:m ranges from 0.05:0.95 to 0.95:0.05, l+m=1,

R 1 is chosen from C 2 -C 12 alkylenes optionally interrupted by at least one oxygen, C 3 -C 8 cycloalkylenes, C 3 -C 10 cycloalkylalkylenes,

R 3 is C 2 -C 12 alkylene,

R 2 and R 4 are independently chosen from the side chains of L- and D-amino acids so that the carbon to which R 2 or R 4 is attached has L or D chirality.

3 . The method as defined in claim 1 , wherein the polymer is in the form of polymer microcapsules.

4 . The method as defined in claim 1 , wherein the polymer is in the form of polymer nanocapsules.

5 . The method as defined in claim 3 , wherein the microcapsules are suspended in a liquid.

6 . The method as defined in claim 1 , wherein the composition is sprayed on the wound.

7 . The method as defined in claim 1 , wherein the biodegradable amino-acid based polymer is devoid of anti-bacterial agents.

8 . The method as defined in claim 1 , wherein the biodegradable amino-acid based polymer is devoid of bacteriophages.

9 . The method as defined in claim 1 , wherein the biodegradable amino-acid based polymer is essentially devoid of bacteriophages.

10 . The method as defined in claim 1 , wherein the polymer is in the form of a film.

11 . The method as defined in claim 1 , wherein the polymer is applied repeatedly on the wound.

12 . The method as defined in claim 11 , wherein the polymer is applied daily on the wound.

13 . The method as defined in claim 12 , wherein the polymer is applied until the wound reaches a predetermined healing status.

14 . The method as defined in claim 1 , wherein the wound is a chronic wound.

15 . The method as defined in claim 14 , wherein the chronic wound is selected from the group consisting of diabetic foot ulcers, pressure ulcers, venous stasis ulcers, and ischemic ulcers.

16 . The method as defined in claim 1 , wherein the composition further comprises at least one of an analgesic and an anti-inflamatory agent.

17 . The method as defined in claim 1 , wherein the composition further comprises at least one of ibuprofen, lidocaine, opioids, and cannabinoids.

18 . The method as defined in claim 3 , wherein the microcapsules consist essentially of the amino-acid based polymer.

19 . The method as defined in claim 3 , wherein the microcapsules consist of the amino-acid based polymer.

20 . The method as defined in claim 4 , wherein the nanocapsules consist essentially of the amino-acid based polymer.

21 . The method as defined in claim 4 , further comprising a permeation enhancer promoting permeation of the nanocapsules in the wound.

22 . The method as defined in claim 1 , wherein the composition further includes at least one additional component selected from the group consisting of: metal ions, zinc ions, silver ions, anti-microbial peptides (AMPs), Human Cathelicidin LL-37, Innate Defense Regulator 1018 peptide (IDR-1018), Human β-defensis (hBD-2 and hBD-3), Pexiganan, Tiger17 peptide, Growth factors (Gfs), granulocyte-macrophage colony-stimulating factor (GM-CSF), basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), stem cells, bone marrow-derived stem cells (BMSCs), adipose-derived stem cells (ADSCs), cellular adhesion molecules (CAMs), antibiotics or antimicrobials, analgesics, polyethylene glycol and anti-inflammatory agents.

23 . The method as defined in claim 1 , wherein the composition is part of a dressing selected from the group consisting of gauzes, transparent films, foams, hydrogels, hydrocolloids, and hydroconductive dressings.

24 . The method as defined in claim 1 , wherein the composition is dispersed in or covalently bonded to the remainder of the dressing.

25 . The method as defined in claim 1 , further comprising degrading the composition in tissues part of the wound or adjacent to the wound.

26 . The method as defined in claim 1 , wherein the composition is in the form of a coating layer coats an implantable device.

27 . The method as defined in claim 26 , wherein the coating layer is designed to completely biodegrade over of predetermined duration, the predetermined duration being one of at least one month and at least one year.

28 . The method as defined in claim 1 , wherein where R 1 is —(CH 2 ) 6 —, R 3 is —(CH 2 ) 8 —, and R 2 and R 4 are the side chain of L-leucine.